Silica-based microencapsulation used in topical dermatologic applications.

"Declarations Competing interestsLJG is an investigator, speaker, or consultant to: Abbvie, Alumis, Arcutis, Amgen, BMS, Cara, Dermavant, DermTech, Highlittl, Janssen, Lilly, Novan, OrthoDerm, SunPharma, Takeda, UCB, Ventyx, Verrica. NDB is an advisor, consultant, and investigator for Galderma and Sol-Gel Technologies. OT and ME are employees of Sol-Gel Technologies. AS is a speaker for Diversity in Dermatology and the American Osteopathic College of Dermatology; had employment or consultation with Amgen, Ortho Dermatologics, Galderma, Regeneron/Sanofi, BMS, Arcutis, Dermavant, Eli Lilly, CeraVe, Verrica; and had a position on advisory board or board of directors or other type of management relationships with: Amgen, Ortho Dermatologics, Galderma, Regeneron/Sanofi, BMS, Arcutis, Dermavant, Eli Lilly, CeraVe, and Verrica. BCG and JPY are employees of Galderma Laboratories. JJ is an investigator in Galderma clinical trials unrelated to the subject matter of this manuscript. She is an investigator and speaker for other companies, none of which represent a conflict of interest for this publication. Conflict of interestLJG is an investigator, speaker, or consultant to: Abbvie, Alumis, Arcutis, Amgen, BMS, Cara, Dermavant, DermTech, Highlittl, Janssen, Lilly, Novan, OrthoDerm, SunPharma, Takeda, UCB, Ventyx, Verrica. NDB is an advisor, consultant, and investigator for Galderma and Sol–Gel Technologies. OT and ME are employees of Sol–Gel Technologies. AS is a speaker for Diversity in Dermatology and the American Osteopathic College of Dermatology; had employment or consultation with Amgen, Ortho Dermatologics, Galderma, Regeneron/Sanofi, BMS, Arcutis, Dermavant, Eli Lilly, CeraVe, Verrica; and had a position on advisory board or board of directors or other type of management relationships with: Amgen, Ortho Dermatologics, Galderma, Regeneron/Sanofi, BMS, Arcutis, Dermavant, Eli Lilly, CeraVe, and Verrica. BCG and JPY are employees of Galderma Laboratories. JJ is an investigator in Galderma clinical trials unrelated to the subject matter of this manuscript. She is an investigator and speaker for other companies, none of which represent a conflict of interest for this publication. Competing interests LJG is an investigator, speaker, or consultant to: Abbvie, Alumis, Arcutis, Amgen, BMS, Cara, Dermavant, DermTech, Highlittl, Janssen, Lilly, Novan, OrthoDerm, SunPharma, Takeda, UCB, Ventyx, Verrica. NDB is an advisor, consultant, and investigator for Galderma and Sol-Gel Technologies. OT and ME are employees of Sol-Gel Technologies. AS is a speaker for Diversity in Dermatology and the American Osteopathic College of Dermatology; had employment or consultation with Amgen, Ortho Dermatologics, Galderma, Regeneron/Sanofi, BMS, Arcutis, Dermavant, Eli Lilly, CeraVe, Verrica; and had a position on advisory board or board of directors or other type of management relationships with: Amgen, Ortho Dermatologics, Galderma, Regeneron/Sanofi, BMS, Arcutis, Dermavant, Eli Lilly, CeraVe, and Verrica. BCG and JPY are employees of Galderma Laboratories. JJ is an investigator in Galderma clinical trials unrelated to the subject matter of this manuscript. She is an investigator and speaker for other companies, none of which represent a conflict of interest for this publication. Conflict of interest LJG is an investigator, speaker, or consultant to: Abbvie, Alumis, Arcutis, Amgen, BMS, Cara, Dermavant, DermTech, Highlittl, Janssen, Lilly, Novan, OrthoDerm, SunPharma, Takeda, UCB, Ventyx, Verrica. NDB is an advisor, consultant, and investigator for Galderma and Sol–Gel Technologies. OT and ME are employees of Sol–Gel Technologies. AS is a speaker for Diversity in Dermatology and the American Osteopathic College of Dermatology; had employment or consultation with Amgen, Ortho Dermatologics, Galderma, Regeneron/Sanofi, BMS, Arcutis, Dermavant, Eli Lilly, CeraVe, Verrica; and had a position on advisory board or board of directors or other type of management relationships with: Amgen, Ortho Dermatologics, Galderma, Regeneron/Sanofi, BMS, Arcutis, Dermavant, Eli Lilly, CeraVe, and Verrica. BCG and JPY are employees of Galderma Laboratories. JJ is an investigator in Galderma clinical trials unrelated to the subject matter of this manuscript. She is an investigator and speaker for other companies, none of which represent a conflict of interest for this publication."